STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Enclomiphene

Also known as

Enclomiphene citrate · Enclomifene (INN-style spelling) · trans-clomiphene · Androxal (Repros development designation; not marketed) · EnCyzix (EU development designation; not authorized) · Enclomiphene HCl (compounded salt discussion) · EC / enclo (forum shorthand)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral tablets / capsules Hormone modulators

Systemic — oral SERM (pure trans isomer of clomiphene); blocks central estrogen feedback so LH/FSH and endogenous testicular testosterone rise axis-wide.

What people say Enclomiphene is the trans isomer of clomiphene and an oral selective estrogen-receptor modulator studied to raise LH, FSH, and endogenous testosterone in men with secondary hypogonadism. It is not FDA-approved for male hypogonadism. Doses people talk about
Six-week Phase II arms6.25 / 12.5 / 25 mg once daily

Randomized oral dose-ranging arms in men with secondary hypogonadism.

Early 14-day dose finding12.5 / 25 / 50 mg once daily

Short comparison with placebo and topical testosterone; later development generally centered at or below 25 mg.

Modern clinic discussion12.5 mg oral

Frequently cited starting amount in clinic and telehealth write-ups, not an approved label or universal standard.

The rows distinguish trial arms from modern practice discussion; they are not a sequence, recommendation, or personal dosing plan.

Half-life & effect duration

Half-life in the body
  • Oral · FDA estimateAbout 10 hours
  • Other formal / secondary estimatesAbout 8 hours or 10–12 hours
Felt duration people report
  • One ongoing-use accountGradual improvement by about 8 weeks, then mood or fluid-retention changes
  • Another accountLab changes without a consistent felt difference
Timing context & sources
How it may feel Accounts range from improved libido, energy, or recovery to no subjective benefit despite higher laboratory values. Insomnia, bloating, mood or libido changes, headache, and visual symptoms appear in some reports, with product identity and co-medications often uncertain.
Cycles people discuss Trials commonly ran for weeks to months; community contexts include continuous clinic use, fertility follow-up, and post-androgen restart blocks. These are different clinical or self-experiment contexts, not one validated cycle. Timing Oral plasma exposure peaks within hours and the parent drug has an approximately ten-hour half-life, while hormone and symptom changes may take weeks and can persist beyond plasma clearance. Around the dose Clock: Same time daily (or on the EOD/E3D days you actually take). With or without food; fed state can delay Tmax in ADME notes. Stacks Reports include use with hCG, aromatase inhibitors, fertility supplements, and tadalafil, but these combinations confound attribution and are not established here as protocols. Access talk Not an FDA-approved male-hypogonadism brand: Androxal/EnCyzix never became a marketed US/EU TRT. 2025–26 access is compounded prescription (Hims, Maximus, FountainTRT, Strut, GameDay, local 503A) or gray research liquid. Labs people mention Scoreboard: Morning total T, free T, LH, FSH, sensitive estradiol, SHBG, CBC/hematocrit, lipids. First recheck ~4–8 weeks, then ~3 months. Random T without LH/FSH/E2 is what those threads call a half-panel. Watch for Vision (SERM class): Blurring, halos, light sensitivity — rarer in pure-enclomiphene write-ups than classic Clomid lore, but treated as stop-and-get-care if visual changes appear. Trial programs included visual acuity / slit-lamp monitoring.
Related
ClomiphenehCGTadalafilAnastrozole

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

FDA's evaluation reports an approximately ten-hour oral plasma half-life for enclomiphene.

Peak plasma exposure was described around two to three hours; hormonal responses last longer than parent-drug plasma exposure.

Small development studies and regulatory summaries; formulation, food, assay, and study-design differences limit precision, and the range does not define a dosing schedule.

  • FDA Pharmacy Compounding Advisory Committee briefing document: enclomiphene citrate (opens in a new tab)FDA Evaluation of Enclomiphene Citrate, Human Safety — Pharmacokinetic Data, report p. 10 (PDF p. 24 of the combined package): rapid oral absorption, approximately 10-hour half-life, and maximum serum concentration at about 2–3 hours; report p. 11 (PDF p. 25) describes the 14-day 12.5/25/50 mg daily study with placebo and topical testosterone.Regulatory review document rather than an approved label; it summarizes sponsor data and FDA concerns and does not establish a current approved use.

Felt duration people report

No dependable single-dose felt window was established by the inspected accounts.

One detailed account described gradual improvement by about eight weeks with later mood and fluid-retention changes; another reported laboratory change without a consistent subjective response.

Self-selected reports, disputed product identity, weak or changing baselines, co-supplements, aromatase-inhibitor use, and dose changes prevent causal timing estimates.

  • Blood work 4 weeks into enclomiphene (opens in a new tab)Original post and same-author follow-up describe 12.5 mg daily use, baseline and follow-up testosterone values, libido and recovery impressions, and a later product-source change.Anonymous uncontrolled account with Tongkat use, weak baseline comparability, and disputed product identity.
  • My enclomiphene journey with bloodwork (opens in a new tab)Post and updates cover 12.5 mg daily use, changing laboratory results and co-medication, gradual subjective change by about eight weeks, and later water retention and mood changes.Anonymous single-person account with anastrozole, dose changes, time-varying confounders, and no blinded control.

Other context in this card

What people say 11

  • Libido / drive / morning wood: Users and clinic narratives report better libido and sexual function when low-T labs actually move into mid-normal — not universal, and high E2 can flip libido the wrong way. forum
  • Mood / energy (when labs fit): Responders describe steadier energy and less “low-T fog”; non-responders and high-E2 cases report flat or worse mood. forum
  • Oral convenience: Daily pill — no pins vs injectable TRT or hCG-heavy protocols. forum
  • PCT / restart talk: Bodybuilding and men’s-health forums list enclomiphene as a SERM option instead of or after clomiphene/tamoxifen, often after an hCG bridge off long TRT or AAS. forum
  • No testicular shutdown story (relative): Discussed as keeping testicular stimulation vs atrophy/suppression on exogenous T alone — still individual and diagnosis-dependent. forum
  • Dose-dependent T rise (short trial): Early oral Androxal-style 14-day arms: ~12.5 mg → mean TT ~412 ng/dL; 25 mg → ~520; 50 mg → ~589 from low/borderline baselines, with free-T rise and less proportional DHT bump than AndroGel in that design. trial
  • Multi-week restoration: Phase II 6-week ladder (6.25 / 12.5 / 25 mg daily) raised TT and gonadotropins vs baseline; higher doses drove stronger LH — with talk of a practical ceiling around 25 mg because Leydig response plateaus (T not pushed to true supra ranges like heavy exogenous T). trial
  • Fertility angle vs topical T: Head-to-heads (e.g. Kim / Kaminetsky-line work) — enclomiphene raised T while sperm concentration stayed usable; gel TRT raised T but crushed sperm counts. Framed as preserving spermatogenesis while restoring T. trial
  • LH/FSH up, not shut down: Opposite of exogenous TRT on the axis — LH/FSH increase rather than suppress, which is the whole fertility / testicular-volume argument. trial
  • Vs clomiphene (clinic series): Similar T lift; 2024 Baylor-style comparative work reported fewer adverse-event signals on enclomiphene — especially decreased libido, reduced energy, and mood changes — and less estradiol climb when switching off racemic clomiphene. trial
  • Cleaner Clomid narrative: Common search framing — “same T mechanism without the long zuclomiphene tail.” Supported by PK and some AE comparisons; not a guarantee of zero SERM sides. forum

Doses people talk about 17

  • Common clinic start: 12.5 mg oral once daily is the most-cited entry dose in modern telehealth/clinic write-ups. forum
  • Ceiling culture: 25 mg daily is the usual upper chronic band in community/clinic talk; chasing higher is framed as diminishing T returns + more E2 pressure, with sparse high-dose long-term data. forum
  • EOD / microdose variants: 12.5 EOD, 6.25 daily, or stepped PCT microdoses (e.g. 6.25 then 3.125) appear in forums; thinner formal evidence than the daily trial arms. forum
  • “Days per week” clinic variant: Some men’s-health write-ups mention ~25 mg three to five days per week rather than strict daily — adherence and lab-guided, not a universal standard. forum
  • PCT chart examples (community only): Multi-week daily SERM blocks at 6.25–25 mg; one public TRT-exit log used ~6.25 mg/day then 3.125 mg/day over several weeks; other logs report 12.5 mg daily, or 12.5 twice daily short-term, or ~25 mg/day for ~6–8 weeks then a taper. Schedules vary widely — not one canonical PCT. forum
  • Product risk: Compounded and gray-market labeled mg can diverge from assay; research-chem “enclo” may be racemic clomiphene or under-dosed — third-party testing and legitimate pharmacy sourcing are recurring cautions. forum
  • 2026 “less is more” frequencies: r/enclomiphene 2026 bloodwork posts copy 12.5 mg EOD, 12.5 mg twice a week (Mon/Thu), 12.5 E3D, or 12.5 E4D after daily 12.5 sent LH/E2 too high. Formal evidence is still the daily 6.25–25 mg trial arms. forum
  • 25 mg daily is no longer the casual opener: 2025 r/Testosterone still has 25 mg ED clinic starts (GameDay-style) with 300s → 900s TT; 2026 comments call that a high dose and tell new people to start 12.5 or 6.25 and space days. forum
  • Hims / Maximus / Fountain / Strut 12.5 mg daily default: Telehealth still opens at 12.5 mg once daily, labs ~4–8 weeks. User-side titration to EOD is often the patient, not the protocol sheet. forum
  • PCT 12.5–25 mg blocks, then taper: 2026 PCT writeups swap enclo in for Clomid (example 25 mg a few days, then 12.5 mg). Not one canonical restart. forum
  • Cautious / sensitive start: 6.25 mg daily (or 6.25 EOD) appears when users want a lower first step or are splitting compounded tabs. forum
  • Titration pattern (clinic narrative): Hold 12.5 mg ~4–6 weeks → morning labs → if TT still soft (examples discussed: still under ~400–450 or ~500 ng/dL targets depending on clinic) and symptoms lag, step to 25 mg daily; recheck ~week 12 then every 3–6 months when stable. forum
  • Early dose-finding also tested 50 mg: 14-day work included 12.5 / 25 / 50 mg vs placebo and AndroGel; T rose dose-dependently, with later programs centering ≤25 mg as the practical ceiling for daily chronic talk. trial
  • Trial up-titration rule (ZA-style): Men not hitting a TT target (e.g. 450 ng/dL cited at week 4) on 12.5 mg were moved to 25 mg in multi-month programs — not everyone needed the higher arm. trial
  • With food / timing: Taken with or without food in practice write-ups; consistent same-time daily habit is the common adherence rule. Fed-state PK can shift Tmax later in formal ADME notes. trial
  • Framing: Discussed / trial-reported ranges only — not medical advice, not a prescription, not product endorsement. forum
  • Phase II ladder (Androxal): Oral 6.25 mg, 12.5 mg, and 25 mg once daily were the core studied arms for secondary hypogonadism. trial

How it may feel 12

  • Days 1–7: Often little subjective change. Mild headache, GI unease, or hot-flash-type warmth can show before labs move. forum
  • Weeks 2–3: Common window where steadier axis effects start to settle after start or a dose change. forum
  • Weeks 4–6: Standard first bloodwork checkpoint in clinic talk (morning TT/free T, LH, FSH, sensitive E2, CBC, lipids, often SHBG/PSA context). Symptom lag can trail lab gains by another 2–4 weeks. forum
  • Weeks 4–8: Typical “does this work for me?” window for energy, libido, and sexual scores in discussion — not overnight. forum
  • Months 2–3: Stable responders describe held libido/energy if labs stay mid-normal and E2 is tolerable; partial responders reassess diagnosis, adherence, sleep/weight, or stack decisions. forum
  • No meaningful lab change ~4–6 weeks: Re-lab and rethink — primary hypogonadism, ongoing opioids, untreated apnea, or residual exogenous-androgen suppression won’t behave like clean secondary cases. forum
  • Labs up, feel not (loud 2026): r/enclomiphene 2026 updates still show TT jumping into the 900s with LH/FSH up while energy, fog, and libido stay flat — high E2 is the first guess, then “SERM at the brain.” Not everyone feels the number. forum
  • Daily-use reports can change over time: Some 12.5 mg daily accounts describe an early improvement followed by insomnia, bloating, or lower libido over later weeks. Users often report spacing doses, but the accounts are uncontrolled and do not establish a corrective schedule. forum
  • Eye pressure / floaters still happen on “clean Clomid”: 2025 r/enclomiphene logs (Maximus, Hallandale, Strut) report blur, floaters, and light sensitivity even at 6.25–12.5 mg. Marketing that enclo has no ocular risk is what those threads argue against. forum
  • Split-tab headache fix: One 2025 r/Testosterone 25 mg daily log split the tablet morning/afternoon and said the first-week headaches left. Same milligrams, different clock. anecdote
  • Peak drug, not peak feel: Oral absorption is relatively fast (peak plasma often cited ~2–3 h in PK write-ups; some isomer-mix sources cite ~4–6 h) — subjective benefits still lag hormonal adaptation. trial
  • Weeks 1–2: Some note early energy/libido ticks; many feel nothing yet. Early 14-day trial data already showed TT into normal band for many — “feel” still individual. trial

Around the dose 5

  • Clock: Same time daily (or on the EOD/E3D days you actually take). With or without food; fed state can delay Tmax in ADME notes. trialforum
  • Lab-timing discussion: Community and clinic accounts compare fasting morning total/free testosterone, LH, FSH, and sensitive estradiol. Some accounts hold the morning dose, but this is an unvalidated sampling convention rather than a universal rule. forum
  • Estradiol-management discussion: Threads debate symptoms, estradiol results, and testosterone-to-estradiol ratios before adding an aromatase inhibitor; ratio cutoffs and self-directed add-ons are community lore, not validated protocols. forum
  • Headache / vision reports: Some users changed dose timing or frequency after headache or visual symptoms. These anecdotes do not establish a mitigation protocol; new visual symptoms remain a medical safety concern. forum
  • After a clomiphene switch: Residual zuclomiphene can complicate early interpretation because it persists longer than enclomiphene. Community warnings against overlapping products reflect isomer exposure, not a validated switch schedule. forum

Cycles people discuss 7

  • Clinic / “TRT alternative” style: Often continuous daily oral use with periodic labs, not short “blast and cruise” cycles — because the goal is sustained endogenous T, not a timed anabolic peak. forum
  • PCT windows: Multi-week post-AAS or post-TRT SERM blocks (sometimes after hCG to restimulate testes first), occasionally stepped down over 4–8+ weeks depending on prior suppression depth. forum
  • Post-TRT restart pattern (discussed): hCG for a bridge while HPTA is asleep → add or switch to enclomiphene 12.5–25 mg daily for ~8–12 weeks → drop hCG and either continue enclo solo or taper off if labs hold. forum
  • Time off / pulse talk: Some pause after stable labs to test whether the axis holds; many who were secondary re-symptomatic after washout restart. forum
  • Fertility timelines: Semen analysis rechecks are often planned around ~3 months (sperm cycle ~70–74 days) when fertility is the endpoint — not week-2 T labs alone. forum
  • Not a substitute for primary failure: Ongoing use does not “fix” failed testes; discussion steers those cases toward exogenous T ± fertility adjuncts instead. forum
  • Trial blocks: Study exposures commonly weeks to ~3–6 months (some safety/extension arms longer); multi-year consumer surveillance is thinner than for labeled TRT products. trial

Timing 8

  • Steady hormonal picture: ~2–3 weeks after start or dose change for a more stable lab/symptom read; many protocols wait to ~4–6 weeks before major titration. forum
  • Morning labs: Fasting morning TT/free T (and LH/FSH/E2) remain the comparison standard in clinic talk — dose timing should be consistent relative to draw habits. forum
  • Missed doses: Short half-life means less accumulation than zuclomiphene; missing a day is often framed as lower drama than missing TRT inject timing — still not an invitation to irregular use. forum
  • Plasma half-life: Roughly ~8–10.5 hours in formal write-ups (EMA assessment ~8 h; common secondary sources ~10–12 h). Far shorter than zuclomiphene (often cited multi-day to multi-week, e.g. ~5–30+ days), which is why racemic Clomid “hangs around.” trial
  • Tmax: Peak plasma commonly described ~2–3 hours after oral dose in enclomiphene-focused summaries; fed state can delay Tmax. trial
  • Why daily dosing: Short half-life supports once-daily (or structured multi-day/week) oral schedules rather than weekly inject logic. trial
  • Clearance window: Drug largely out of plasma on the order of ~2 days after stopping; hormonal effects outlast parent drug. trial
  • Hormonal lag after stop: LH and testosterone can remain elevated up to about a week after the last dose in study narratives; baseline drift often discussed over subsequent weeks (~within a month in some pilot/stop observations). trial

More on what it is 8

  • What it is: The purified *trans* isomer of clomiphene citrate (Clomid is a ~62% enclomiphene / ~38% zuclomiphene racemic mix). Standalone oral SERM — not a peptide, not exogenous testosterone. trial
  • Why people talk about it: Raise endogenous T, LH, and FSH while aiming to keep fertility open — framed as “restoration instead of replacement” vs gel/inject TRT. trial
  • Mechanism (plain): Antagonizes estrogen receptors at hypothalamus/pituitary → less negative feedback → more GnRH drive → more LH/FSH → Leydig cells make more testosterone and Sertoli side supports spermatogenesis. trial
  • Vs Clomid isomer story: Enclomiphene is the short-lived anti-estrogenic workhorse for the T rise; zuclomiphene is longer-lived, more estrogen-agonist-leaning, and is the isomer people blame for mood/vision/libido drama. trial
  • Evidence base: Multiple Phase II/III-style Androxal programs (doses 6.25–25 mg daily; some early arms to 50 mg) raised total/free T and LH/FSH and held sperm better than topical T in head-to-heads. trial
  • Regulatory honesty: Not FDA-approved for male hypogonadism (Androxal CRL / incomplete clinical-benefit design issues; development later discontinued). EMA refused EnCyzix (2018). U.S. use discussed as compounded prescription-only, not a labeled TRT brand. trial
  • Who it can work for (discussed): Secondary / hypogonadotropic-leaning low T (intact testes + responsive HPG). Primary testicular failure and fully suppressed post-heavy-AAS axes are commonly called non- or weak-responders. trial
  • Research-only framing here: Community and trial ranges are descriptive — not dosing advice, not a prescription, not a claim of safety for unsupervised use. forum

Stacks 11

  • Solo first: Most clinic and forum guidance starts monotherapy 12.5–25 mg daily with labs — stacking is additive complexity, not default. forum
  • + hCG (selective): Discussed when LH rises but T stays flat (Leydig fatigue after long TRT), aggressive fertility goals, or post-TRT restart bridges. Community/clinic ballpark often 250–500 IU SC 2–3×/week (sometimes higher in formal hypogonadotropic fertility protocols with clomiphene-class agents). Dual LH drive can raise E2 more. forum
  • Post-TRT restart combo: Enclomiphene 12.5–25 mg daily + hCG ~500 IU 3×/week for ~8–12 weeks, then drop hCG — a commonly written pattern, not a single validated universal protocol. forum
  • + aromatase inhibitor (symptom + lab driven): Anastrozole-class microdoses (community examples ~0.25–0.5 mg once or twice weekly) only when sensitive E2 is high *with* symptoms (nipple sensitivity, water, moodiness, paradoxically low libido). Over-crushing E2 (e.g. under ~20 pg/mL talk) is a frequent caution (joints, libido, lipids). forum
  • E2 self-care adjuncts (softer evidence): DIM 100–200 mg, weight loss if high adiposity aromatization, sleep/alcohol cleanup — framed as mild support, not equal to a true AI when E2 is clearly high. forum
  • Fertility support stack (discussed): Enclomiphene 12.5–25 mg daily + CoQ10 (often 200 mg 1–2×/day ubiquinol talk) + L-carnitine (~1 g 2×/day) + vitamin D to sufficiency + zinc (~15 mg) — semen recheck ~3 months. forum
  • PCT stacks: Enclomiphene in place of or sequenced with other SERMs after AAS; sometimes after or with hCG. Dual long-term SERM (enclo + tamoxifen) is often called redundant outside short restart templates. forum
  • Avoid canceling the mechanism: Exogenous testosterone + enclomiphene is widely called self-defeating — T negative-feedback fights the LH/FSH rise enclomiphene is trying to create. forum
  • Avoid re-adding zuclomiphene: Stacking enclomiphene with clomiphene just puts the long estrogenic isomer back — generally called pointless. forum
  • Lifestyle co-factors: Resistance training, sleep, weight management, and treating apnea are repeatedly credited for real T/symptom gains alongside any SERM. forum
  • ED meds adjacency: PDE5 inhibitors (e.g. tadalafil) appear in user logs alongside enclomiphene for sexual performance — separate mechanism, not a hormone stack. forum

Access talk 4

  • Not an FDA-approved male-hypogonadism brand: Androxal/EnCyzix never became a marketed US/EU TRT. 2025–26 access is compounded prescription (Hims, Maximus, FountainTRT, Strut, GameDay, local 503A) or gray research liquid. trialforum
  • Telehealth 12.5 mg capsule is the default SKU: Compounded 6.25 / 12.5 / 25 mg. A clinic fill is not a research-chem COA. Some endocrinologists still refuse to write it and keep racemic Clomid because of the approval gap. forum
  • Hims combo pills: 2026 Testosterone Rx pages advertise compounded enclomiphene alone or enclomiphene + tadalafil in one daily pill (Rx+ also stacks zinc / B6 / B12 / L-arginine). Separate mechanisms — read the label. forum
  • Research-chem liquid: 2025 r/enclomiphene HPLC posts argue a single peak means “not Clomid,” not that the milligram and isomer are proven. Identity risk stays. forum

Labs people mention 5

  • Scoreboard: Morning total T, free T, LH, FSH, sensitive estradiol, SHBG, CBC/hematocrit, lipids. First recheck ~4–8 weeks, then ~3 months. Random T without LH/FSH/E2 is what those threads call a half-panel. forum
  • High T, high E2, dead libido: 2026 example logs (12.5 mg daily: TT ~400s → ~900s, E2 45 → 57–83) then switch to EOD. Ratio talk (~1:10–1:18) is used to argue against an automatic AI. forum
  • SHBG can rise with total T: Daily enclo logs show SHBG climbing so free T lags the headline TT. People then space doses or chase free T, not just the total. forum
  • Hematocrit is not “TRT-only”: A 2026 r/endocrinology log went HCT 42.5% → 51.5% over a year on enclo with TT stuck ~450s. CBC still gets watched. forumanecdote
  • If LH/FSH never move: Primary testicular failure or leftover exogenous T — enclo cannot manufacture Leydig function. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 12

  • Elevated estradiol (most-discussed practical issue): Rising T → more substrate for aromatase → moodiness, water retention, nipple sensitivity/gyno worry, or paradoxically worse libido. Higher body fat increases this risk in discussion. forum
  • Mood / libido / energy can still go wrong: Cleaner than clomiphene in comparative series does not mean risk-free — irritability, flat affect, or libido drops still get reported, especially with E2 mismatch. forum
  • Non-responders: Primary hypogonadism, irreversible testicular damage, or deep post-AAS/TRT suppression may show little T rise — labs (LH/FSH pattern) should reframe expectations. forum
  • Source / regulatory: No broad FDA-approved male-hypogonadism brand; compounded potency varies; gray-market identity risk; development discontinued as a commercial NDA path. forum
  • Drug-interaction / medical cautions: Not for unsupervised self-experimentation; estrogen-sensitive conditions, prior VTE, uncontrolled polycythemia, and serious hepatic disease are standard clinical red-flag themes for SERM/T-axis drugs. forum
  • Trial common AEs: Headache, nausea, dizziness, hot flashes, blurred vision, muscle spasms — usually described as mild/transient in study summaries; long-term independent safety data still limited. trial
  • Vs clomiphene AE rates (2024 comparative): Enclomiphene arms/switch cohorts showed significantly less decreased libido, reduced energy, and mood change vs clomiphene; overall AE rates lower in reported analyses — still observational/clinic-scale, not a lifelong guarantee. trial
  • Vision (SERM class): Blurring, halos, light sensitivity — rarer in pure-enclomiphene write-ups than classic Clomid lore, but treated as stop-and-get-care if visual changes appear. Trial programs included visual acuity / slit-lamp monitoring. trial
  • Hematocrit / CBC / lipids / PSA: Axis stimulation and higher T still put polycythemia, lipid shifts, and PSA monitoring on clinic checklists; elevated hematocrit and VTE-class signals appear in broader safety discussions (low absolute rates in some older summaries, not zero). trial
  • Thromboembolic / cardiac / psychiatric signals: Some regulatory/trial safety narratives list higher rates of VTE, cardiac disorders, eye disorders, and psychiatric events vs placebo in program data — context and adjudication matter; not dismissed as impossible. trial
  • Fertility not guaranteed: Relative sperm preservation vs exogenous T is trial-supported; age, baseline SA, varicocele, and duration of prior suppression still dominate outcomes. trial
  • Sport ban: Prohibited-class status for tested athletes (clomiphene/enclomiphene family). trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →